Healthcare Sector

ELDN

Market Tracker

  • ELDN (Selected)

    Eledon Pharmaceuticals, Inc.

ELDN Most Active Options Strike Prices Whale BUY Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the ASK side) over the past 5 trading days.

ELDN Most Active Options Strike Prices Whale SALES Activity - 5 day

Loading Data..

Represents the strikes that had the highest premium of whale flow (on the BID side) over the past 5 trading days.

ELDN Open Interest Trend

Loading Data..

Total Open Interest of Calls & Puts across all strikes and expirations over the past 16 trading days.

ELDN Largest 1-Day Open Interest Movements

Expires Type Strike OI Change Percent
08/16/2024 CALL $5.00 65 +10 +18.18%
04/19/2024 CALL $2.50 95 0
04/19/2024 CALL $5.00 1 0
04/19/2024 CALL $7.50 0 0
04/19/2024 PUT $2.50 8 0
04/19/2024 PUT $5.00 0 0
11/15/2024 CALL $2.50 10 0
11/15/2024 CALL $5.00 0 0
11/15/2024 CALL $7.50 0 0
11/15/2024 PUT $2.50 6 0
11/15/2024 PUT $5.00 0 0
11/15/2024 PUT $7.50 0 0

Contracts with largest changes in open interest from the previous trading day to the current/most recent.

ELDN Major Holders

Name Pct Held Shares Total
Vanguard Total Stock Market Index Fund 3.34% 460k 634.8k
Vanguard Extended Market Index Fund 1.46% 201.26k 277.74k
Fidelity Extended Market Index Fund 0.55% 75.45k 104.12k
iShares Micro Cap ETF 0.17% 22.83k 31.51k
Fidelity Total Market Index Fund 0.13% 18.47k 25.48k
Fidelity Series Total Market Index Fund 0.12% 16.81k 23.2k
Vanguard Institutional Index-Inst Total Stock Market Ind 0.10% 13.26k 18.3k
Fidelity NASDAQ Composite Index Fund 0.08% 10.48k 14.46k
DFA U.S. Core Equity 2 Portfolio 0.04% 5.08k 7.01k
DFA U.S. Vector Equity Portfolio 0.03% 4.11k 5.67k

ELDN News

  • Eledon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Operating and Financial Results

    03/28 04:01 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Announces 12th Participant Enrolled in Phase 2 BESTOW Trial Evaluating Tegoprubart for the Prevention of Organ Rejection

    03/25 04:56 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Announces Use of Tegoprubart in First-ever Transplant of Genetically Modified Kidney from a Pig to a Human

    03/21 10:31 am

    GlobeNewswire Inc.

    Read more
  • Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    02/13 08:01 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Highlights Recent Business Milestones and Provides 2024 Outlook

    01/04 05:40 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    12/04 07:00 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Present at Noble Capital Markets' Emerging Growth Equity Conference

    11/29 05:05 pm

    GlobeNewswire Inc.

    Read more
  • Expert Ratings for Eledon Pharma

    11/13 11:00 am

    Benzinga

    Read more
  • Eledon Pharmaceuticals Reports Third Quarter 2023 Operating and Financial Results

    11/09 05:01 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals, Inc. (ELDN) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?

    11/09 10:55 am

    Zacks Investment Research

    Read more
  • Eledon Pharmaceuticals to Present at Jefferies London Healthcare Conference

    11/08 05:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Reports Updated Data from Ongoing Phase 1b Trial Evaluating Tegoprubart for Prevention of Rejection in Kidney Transplantation

    11/02 09:05 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Strengthens Leadership Team with Appointment of Eliezer Katz, M.D., FACS as Chief Medical Officer

    10/23 07:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Present Data from Ongoing Phase 1b Trial of Tegoprubart in Patients Undergoing Kidney Transplantation at the American Society of Nephrology Kidney Week 2023 Annual Meeting

    10/13 07:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Appoints Kidney Transplant Specialist Dr. Allan Douglas Kirk to Board of Directors

    10/02 07:00 am

    GlobeNewswire Inc.

    Read more
  • Benzinga's Top Ratings Upgrades, Downgrades For September 27, 2023

    09/27 11:00 am

    Benzinga

    Read more
  • Eledon Pharmaceuticals Announces Use of Tegoprubart anti-CD40L Antibody in Second-ever Transplant of Genetically Modified Heart from a Pig to a Human

    09/25 07:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Participate at the 2023 Cantor Fitzgerald Global Healthcare Conference

    09/20 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Appoints Industry Veteran James Robinson to its Board of Directors

    09/11 07:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Present at Jefferies Healthcare Conference

    06/02 08:00 am

    GlobeNewswire Inc.

    Read more
  • Why Chewy Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket

    06/01 07:55 am

    Benzinga

    Read more
  • Eledon Reports Data from Ongoing Phase 1b Trial Evaluating Tegoprubart in Patients Undergoing Kidney Transplantation at World Congress of Nephrology

    03/31 06:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2022 Operating and Financial Results

    03/30 04:01 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Report Fourth Quarter and Full Year 2022 Financial Results on Thursday, March 30, 2023

    03/23 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Present at SVB Securities Global Biopharma Conference

    02/08 05:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Provides Business and Pipeline Updates

    01/09 09:31 am

    GlobeNewswire Inc.

    Read more
  • C-Path's Transplant Therapeutics Consortium Receives EMA Qualification Opinion for iBox Scoring System

    12/21 05:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Report Third Quarter 2022 Financial Results on Monday, November 14, 2022

    11/03 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Announces Upcoming Presentations at ASN’s Kidney Week 2022 and NEALS

    10/24 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Present at Ladenburg Thalmann Healthcare Conference

    09/22 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Receives FDA Clearance of IND Application to Evaluate Tegoprubart for the Prevention of Rejection in Kidney Transplant Recipients

    08/01 05:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    06/10 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Penny Stocks To Buy Now? 4 To Watch This Week

    05/31 09:49 am

    PennyStocks

    Read more
  • Eledon Announces Positive Topline Results from Phase 2a Trial of Tegoprubart Demonstrating Safety, Target Engagement, and Biomarker Response in Patients Living with Amyotrophic Lateral Sclerosis

    05/31 06:00 am

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Report First Quarter 2022 Financial Results on Thursday, May 12, 2022

    05/05 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Participate in 18th Annual Noble Capital Markets Investor Conference

    04/18 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon to Host Virtual R&D Day on Thursday, April 28, 2022

    04/14 04:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Reports Fourth Quarter and Full-Year 2021 Operating and Financial Results

    03/24 04:01 pm

    GlobeNewswire Inc.

    Read more
  • The Daily Biotech Pulse: Novartis Prostate Cancer Drug Lands FDA Approval, Ligand Announces SPAC Deal To Spin Off Antibody Business, Lilly's Lung Cancer Therapy Hit With CRL

    03/24 08:10 am

    Benzinga

    Read more
  • Eledon Pharmaceuticals to Participate in 11th Annual SVB Leerink Global Healthcare Conference

    02/08 05:05 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals to Participate in January 2022 Investor Conferences

    12/27 06:17 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Reports Third Quarter 2021 Operating and Financial Results

    11/11 05:05 pm

    GlobeNewswire Inc.

    Read more
  • The Daily Biotech Pulse: Eisai-Gilead Tout Positive Phase 2 Data For New Alzheimer's Treatment, Compugen Spikes On Bristol-Myers Investment, Vaxxinity Debuts

    11/11 09:03 am

    Benzinga

    Read more
  • Eledon Pharmaceuticals CEO David-Alexandre C. Gros, M.D., to Present at CareDx Virtual Transplant Innovation Day during ASN Kidney Week 2021

    11/04 05:34 pm

    GlobeNewswire Inc.

    Read more
  • Eledon Pharmaceuticals Announces Presentation on AT-1501 at the Virtual 2021 Northeast Amyotrophic Lateral Sclerosis Consortium

    10/07 07:51 am

    GlobeNewswire Inc.

    Read more
  • The Daily Biotech Pulse: Takeda Suspends Studies On Safety Scare, Acer's Sleep Disorder Drug Filing Accepted For Review, Voyager's Licensing Options Deal

    10/06 07:33 am

    Benzinga

    Read more
  • Eledon Pharmaceuticals Announces Upcoming Presentation on AT-1501 at the Virtual 2021 International Pancreas and Islet Transplantation Association Congress

    10/05 04:22 pm

    GlobeNewswire Inc.

    Read more
  • The Daily Biotech Pulse: J&J Files For Booster Dose Authorization, Gemini Restructures, Strata Skin CFO Departs, Kaleido Reports Positive Readout

    10/05 08:01 am

    Benzinga

    Read more
  • The Daily Biotech Pulse: Merck Rallies On Antiviral Pill Data, Gilead Files For Yescarta Label Expansion, Exscientia IPO

    10/01 07:56 am

    Benzinga

    Read more
  • The Daily Biotech Pulse: Merck Confirms Acceleron Purchase, Regeneron Touts COVID-19 Antibody Cocktail Data, Takeda In-Licenses Huntington's Disease Drug

    09/30 07:43 am

    Benzinga

    Read more
👀

Follow the Whales in real-time.

🎁

Take 50% OFF With Code: